SWOG-9239 Reduction of Immunosuppression Plus Interferon Alfa and Combination Chemotherapy in Treating Patients With Malignant Tumors That Develop After Organ Transplant
Completed
RATIONALE: Reducing the amount of drugs used to prevent transplant rejection may help a person's body kill tumor cells. Giving biological therapy, such as interferon alfa, which may interfere with the growth of cancer cells, or combination chemotherapy, which uses different ways to stop tumor cells from dividing so they stop growing or die, may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of reducing immunosuppression, and giving interferon alfa and combination chem... Read More
Gender:
ALL
Ages:
15 years and above
Trial Updated:
01/22/2013
Locations: Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma +1 locations
Conditions: Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
S9716: Combination Chemotherapy in Treating Patients With Merkel Cell Cancer
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining cyclophosphamide, methotrexate, and fluorouracil in treating patients with Merkel cell cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/05/2012
Locations: Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma +1 locations
Conditions: Neuroendocrine Carcinoma of the Skin
A Study of Mycophenolate Mofetil (CellCept) in Management of Patients With Lupus Nephritis.
Completed
This 2 arm study assessed the efficacy of Mycophenolate Mofetil (MMF; CellCept) compared to cyclophosphamide in inducing a response in patients with lupus nephritis, and the long term efficacy of MMF compared to azathioprine in maintaining remission and renal function. Patients were randomized to receive either MMF (1.5 g twice daily \[bid\]) or cyclophosphamide (0.5-1.0 g/m\^2 in monthly pulses) in the induction phase. Those patients meeting criteria for response were re-randomized for entry in... Read More
Gender:
ALL
Ages:
Between 12 years and 75 years
Trial Updated:
10/31/2011
Locations: Not set, Oklahoma City, Oklahoma
Conditions: Lupus Nephritis
Adjuvant Epirubicin/Cytoxan Followed By A Taxane VS. Epirubicin/Taxane As Treatment For Node-Positive Breast Cancer
Completed
The purpose of this study is to compare two combinations of drugs, epirubicin given with a taxane (ET) or epirubicin given with cyclophosphamide (cytoxan) and followed by a taxane to see if one of the combinations is better at preventing or delaying the time for breast cancer recurrence and death after 3 years. The study will also evaluate the side effects of both treatment combinations.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/24/2011
Locations: Pfizer Investigational Site, Lawton, Oklahoma +1 locations
Conditions: Adenocarcinoma